AJCN EB Program 2010 Early Registration
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamers, Y.
Right arrow Articles by Pietrzik, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamers, Y.
Right arrow Articles by Pietrzik, K.
Agricola
Right arrow Articles by Lamers, Y.
Right arrow Articles by Pietrzik, K.
American Journal of Clinical Nutrition, Vol. 84, No. 1, 156-161, July 2006
© 2006 American Society for Nutrition


ORIGINAL RESEARCH COMMUNICATION

Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age1,2,3,4

Yvonne Lamers, Reinhild Prinz-Langenohl, Susanne Brämswig and Klaus Pietrzik

1 From the Department of Nutrition and Food Sciences, Pathophysiology of Nutrition, University of Bonn, Bonn, Germany

Background: For the primary prevention of neural tube defects (NTDs), public health authorities recommend women of childbearing age to take 400 µg folic acid/d 4 wk before conception and during the first trimester. The biologically active derivate [6S]-5-methyltetrahydrofolate ([6S]-5-MTHF) could be an alternative to folic acid.

Objective: We investigated the effect of supplementation with [6S]-5-MTHF compared with that of folic acid on red blood cell folate concentration, an indicator of folate status.

Design: The study was designed as a double-blind, randomized, placebo-controlled intervention trial. Healthy women (n = 144) aged 19–33 y received 400 µg folic acid, the equimolar amount of [6S]-5-MTHF (416 µg), 208 µg [6S]-5-MTHF, or placebo as a daily supplement for 24 wk. Red blood cell and plasma folate concentrations were measured at baseline and at 4-wk intervals.

Results: The increase in red blood cell folate over time was significantly higher in the group receiving 416 µg [6S]-5-MTHF/d than in the groups receiving 400 µg folic acid/d or 208 µg [6S]-5-MTHF/d (P < 0.001). No plateau was reached in red blood cell folate concentration in the 3 treatment groups during 24 wk of intervention; however, plasma folate plateaued after 12 wk.

Conclusions: We showed that administration of [6S]-5-MTHF is more effective than is folic acid supplementation at improving folate status. In addition, the study indicates that the recommended period for preconceptional folic acid supplementation should be extended to >4 wk for maximal prevention of NTDs based on folate concentrations. [6S]-5-MTHF might be an efficient and safe alternative to folic acid.

Key Words: Red blood cell folate • 5-methyltetrahydrofolate • folic acid • preconception supplementation • neural tube defect




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
S. W. Bailey and J. E. Ayling
From the Cover: The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake
PNAS, September 8, 2009; 106(36): 15424 - 15429.
[Abstract] [Full Text] [PDF]


Home page
Ann Clin BiochemHome page
D J. Bakker, L. T W de Jong-van den Berg, and M R. Fokkema
Controlled study on folate status following folic acid supplementation and discontinuation in women of child-bearing age
Ann Clin Biochem, May 1, 2009; 46(3): 231 - 234.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
L. Hao, Q.-H. Yang, Z. Li, L. B Bailey, J.-H. Zhu, D. J Hu, B.-L. Zhang, J D. Erickson, L. Zhang, J. Gindler, et al.
Folate status and homocysteine response to folic acid doses and withdrawal among young Chinese women in a large-scale randomized double-blind trial
Am. J. Clinical Nutrition, August 1, 2008; 88(2): 448 - 457.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
I. Ifergan, G. Jansen, and Y. G. Assaraf
The Reduced Folate Carrier (RFC) Is Cytotoxic to Cells under Conditions of Severe Folate Deprivation: RFC AS A DOUBLE EDGED SWORD IN FOLATE HOMEOSTASIS
J. Biol. Chem., July 25, 2008; 283(30): 20687 - 20695.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
Y. Lamers and K. Pietrzik
Reply to EP Quinlivan
Am. J. Clinical Nutrition, May 1, 2008; 87(5): 1538 - 1539.
[Full Text] [PDF]


Home page
J. Nutr.Home page
F. L. Crowe, C. M. Skeaff, J. A. McMahon, S. M. Williams, and T. J. Green
Lowering Plasma Homocysteine Concentrations of Older Men and Women with Folate, Vitamin B-12, and Vitamin B-6 Does Not Affect the Proportion of (n-3) Long Chain Polyunsaturated Fatty Acids in Plasma Phosphatidylcholine
J. Nutr., March 1, 2008; 138(3): 551 - 555.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
K. Pietrzik, Y. Lamers, S. Bramswig, and R. Prinz-Langenohl
Calculation of red blood cell folate steady state conditions and elimination kinetics after daily supplementation with various folate forms and doses in women of childbearing age
Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1414 - 1419.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
A. M. Abdel Nour, D. Ringot, J.-L. Gueant, and A. Chango
Folate receptor and human reduced folate carrier expression in HepG2 cell line exposed to fumonisin B1 and folate deficiency
Carcinogenesis, November 1, 2007; 28(11): 2291 - 2297.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by The American Society for Nutrition